Ankit Madan1, Joshua Siglin2, Aleem Khan3. 1. Department of Internal Medicine, SOVAH Cancer Center, Danville, VA, USA. 2. Department of Radiation oncology, Duke University, Raleigh, NC, USA. 3. Department of Psychiatry, Salem VA medical Center, University of Virginia School of Medicine, Salem, VA, USA.
Abstract
Coronavirus disease-2019 (COVID-19) has emerged as a novel infection which has spread rapidly across the globe and currently presents a grave threat to the health of vulnerable patient populations like those with malignancy, elderly, and immunocompromised. Healthcare systems across the world are grappling with the detrimental impact of this pandemic while learning about this novel disease and concurrently developing vaccines, strategies to mitigate its spread, and treat those infected. Cancer patients today face with a unique situation. They are susceptible to severe clinically adverse events and higher mortality from COVID-19 infection as well as morbidity and mortality from their underlying malignancy. Conclusion: Our review suggests increased risk of mortality and serious clinical events from COVID-19 infection in cancer patients. However, risk of adverse events does not seem to be increased by cancer therapies. True impact of COVID-19 on cancer patients will unravel over the next few months. We have also reviewed clinical features of COVID-19, recent recommendations from various medical, surgical, and radiation oncology societies for major solid tumor types like lung, breast, colorectal, and prostate cancer during the duration of this pandemic.
Coronavirus disease-2019 (COVID-19) has emerged as a novel infection which has spread rapidly across the globe and currently presents a grave threat to the health of vulnerable patient populations like those with malignancy, elderly, and immunocompromised. Healthcare systems across the world are grappling with the detrimental impact of this pandemic while learning about this novel disease and concurrently developing vaccines, strategies to mitigate its spread, and treat those infected. Cancerpatients today face with a unique situation. They are susceptible to severe clinically adverse events and higher mortality from COVID-19infection as well as morbidity and mortality from their underlying malignancy. Conclusion: Our review suggests increased risk of mortality and serious clinical events from COVID-19infection in cancerpatients. However, risk of adverse events does not seem to be increased by cancer therapies. True impact of COVID-19 on cancerpatients will unravel over the next few months. We have also reviewed clinical features of COVID-19, recent recommendations from various medical, surgical, and radiation oncology societies for major solid tumor types like lung, breast, colorectal, and prostate cancer during the duration of this pandemic.
Authors: Carsten Palnæs Hansen; Jan Henrik Storkholm; Martin Hylleholt Sillesen; Paul Suno Krohn; Stefan Kobbelgaard Burgdorf; Jens Georg Hillingsø Journal: BMC Surg Date: 2022-05-21 Impact factor: 2.030
Authors: Nikhil V Kotha; Abhishek Kumar; Tyler J Nelson; Edmund M Qiao; Alex S Qian; Rohith S Voora; Rana R McKay; Brent S Rose; Tyler F Stewart Journal: Urol Oncol Date: 2022-02-23 Impact factor: 2.954
Authors: Ainsley Ryan Yan Bin Lee; Shi Yin Wong; Louis Yi Ann Chai; Soo Chin Lee; Matilda Xinwei Lee; Mark Dhinesh Muthiah; Sen Hee Tay; Chong Boon Teo; Benjamin Kye Jyn Tan; Yiong Huak Chan; Raghav Sundar; Yu Yang Soon Journal: BMJ Date: 2022-03-02
Authors: Jaime Monserrat Villatoro; Gina Mejía-Abril; Lucía Díaz García; Pablo Zubiaur; María Jiménez González; Guillermo Fernandez Jimenez; Inés Cancio; José Ramón Arribas; Carmen Suarez Fernández; Jesús Mingorance; Julio García Rodríguez; José Ramón Villagrasa Ferrer; Antonio J Carcas; Jesús Frías; Francisco Abad-Santos; Alberto M Borobia; Elena Ramírez Journal: Pharmaceuticals (Basel) Date: 2022-01-08
Authors: Andrea Alexander; Stephen Fung; Martin Eichler; Nadja Lehwald-Tywuschik; Vasuki Uthayakumar; Sami-Alexander Safi; Christian Vay; Hany Ashmawy; Sinan Kalmuk; Alexander Rehders; Sascha Vaghiri; Wolfram Trudo Knoefel Journal: Int J Environ Res Public Health Date: 2022-03-21 Impact factor: 3.390